Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free OPTH Stock Alerts

Optimi Health (OPTH) Competitors

$4.85 -0.20 (-3.96%)
As of 03:59 PM Eastern
Compare

OPTH vs. CPIX, ZYBT, PLYX, NRXP, and RFL

Should you buy Optimi Health stock or one of its competitors? Optimi Health's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Zhengye Biotechnology (ZYBT), Polaryx Therapeutics (PLYX), NRx Pharmaceuticals (NRXP), and Rafael (RFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Optimi Health compare to Cumberland Pharmaceuticals?

Optimi Health (NASDAQ:OPTH) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Optimi Health has higher earnings, but lower revenue than Cumberland Pharmaceuticals. Optimi Health is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Optimi Health$290K95.83-$1.12M-$0.36N/A
Cumberland Pharmaceuticals$22.30M5.23-$2.84M-$0.71N/A

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Optimi Health has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Optimi Health's return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Optimi HealthN/A N/A N/A
Cumberland Pharmaceuticals -34.40%-26.77%-8.97%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Optimi Health
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cumberland Pharmaceuticals had 5 more articles in the media than Optimi Health. MarketBeat recorded 5 mentions for Cumberland Pharmaceuticals and 0 mentions for Optimi Health. Optimi Health's average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.78 indicating that Optimi Health is being referred to more favorably in the media.

Company Overall Sentiment
Optimi Health Neutral
Cumberland Pharmaceuticals Negative

Summary

Optimi Health beats Cumberland Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Optimi Health compare to Zhengye Biotechnology?

Optimi Health (NASDAQ:OPTH) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Optimi Health has higher earnings, but lower revenue than Zhengye Biotechnology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Optimi Health$290K95.83-$1.12M-$0.36N/A
Zhengye Biotechnology$116.36M0.73-$9.98MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Optimi Health
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Zhengye Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Zhengye Biotechnology had 5 more articles in the media than Optimi Health. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 0 mentions for Optimi Health. Zhengye Biotechnology's average media sentiment score of 0.29 beat Optimi Health's score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Optimi Health Neutral
Zhengye Biotechnology Neutral

Company Net Margins Return on Equity Return on Assets
Optimi HealthN/A N/A N/A
Zhengye Biotechnology N/A N/A N/A

Summary

Optimi Health and Zhengye Biotechnology tied by winning 3 of the 6 factors compared between the two stocks.

How does Optimi Health compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Polaryx Therapeutics' average media sentiment score of 0.00 equaled Optimi Health'saverage media sentiment score.

Company Overall Sentiment
Polaryx Therapeutics Neutral
Optimi Health Neutral

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A N/A N/A
Optimi Health N/A N/A N/A

Optimi Health has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Optimi Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/A-$8.98M-$0.05N/A
Optimi Health$290K95.83-$1.12M-$0.36N/A

Polaryx Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 300.94%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Optimi Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Optimi Health
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Polaryx Therapeutics beats Optimi Health on 4 of the 7 factors compared between the two stocks.

How does Optimi Health compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A -202.92%
Optimi Health N/A N/A N/A

NRx Pharmaceuticals currently has a consensus target price of $34.50, suggesting a potential upside of 929.85%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe NRx Pharmaceuticals is more favorable than Optimi Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Optimi Health
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Optimi Health has lower revenue, but higher earnings than NRx Pharmaceuticals. Optimi Health is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M98.68-$28.62M-$1.09N/A
Optimi Health$290K95.83-$1.12M-$0.36N/A

In the previous week, NRx Pharmaceuticals had 10 more articles in the media than Optimi Health. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 0 mentions for Optimi Health. Optimi Health's average media sentiment score of 0.00 beat NRx Pharmaceuticals' score of -0.53 indicating that Optimi Health is being referred to more favorably in the news media.

Company Overall Sentiment
NRx Pharmaceuticals Negative
Optimi Health Neutral

Summary

NRx Pharmaceuticals beats Optimi Health on 9 of the 13 factors compared between the two stocks.

How does Optimi Health compare to Rafael?

Rafael (NYSE:RFL) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rafael
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Optimi Health
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Rafael's average media sentiment score of 0.00 equaled Optimi Health'saverage media sentiment score.

Company Overall Sentiment
Rafael Neutral
Optimi Health Neutral

Optimi Health has lower revenue, but higher earnings than Rafael. Optimi Health is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rafael$920K111.91-$30.52M-$0.68N/A
Optimi Health$290K95.83-$1.12M-$0.36N/A

Optimi Health has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Optimi Health's return on equity of 0.00% beat Rafael's return on equity.

Company Net Margins Return on Equity Return on Assets
Rafael-3,321.74% -41.27% -35.32%
Optimi Health N/A N/A N/A

11.3% of Rafael shares are held by institutional investors. 32.9% of Rafael shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Optimi Health beats Rafael on 6 of the 11 factors compared between the two stocks.

Get Optimi Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPTH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPTH vs. The Competition

Export
MetricOptimi HealthPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$27.79M$11.95B$7.06B$12.95B
Dividend YieldN/A2.69%2.58%10.20%
P/E Ratio-13.47788.52269.7524.74
Price / Sales95.83967.70652.34108.60
Price / CashN/A15.1228.8937.44
Price / BookN/A10.3311.276.42
Net Income-$1.12M$2.77B$3.45B$347.12M
7 Day PerformanceN/A2.06%3.57%2.48%
1 Month Performance5.66%-1.55%-0.58%-1.04%
1 Year PerformanceN/A191.36%77.53%23.22%

Optimi Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPTH
Optimi Health
0.7035 of 5 stars		$4.85
-4.0%		N/AN/A$27.79M$290KN/AN/A
CPIX
Cumberland Pharmaceuticals
0.3752 of 5 stars		$7.68
+1.7%		N/A+141.5%$113.12M$44.52MN/A80
ZYBT
Zhengye Biotechnology
0.596 of 5 stars		$2.09
-11.4%		N/A-63.7%$111.84M$16.64MN/A278
PLYX
Polaryx Therapeutics
3.3023 of 5 stars		$2.22
-0.9%		$8.50
+282.9%		N/A$111.65MN/AN/A11
NRXP
NRx Pharmaceuticals
2.0581 of 5 stars		$3.09
+1.0%		$38.25
+1,137.9%		+42.1%$110.68M$1.23MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OPTH) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The ultimate IPO unicorn
Anthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...
Weiss Ratings | Sponsoredtc pixel
A $5 stock inside Kennedy Space Center?
A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...
Freedom Financial | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Wall Street owns 88%. You don’t know the name.
Institutions already control 88% of this company's shares. BlackRock holds roughly 32 million shares, Vanguard...
Monument Traders Alliance | Sponsoredtc pixel